COMBINED CHEMOREDUCTION AND ADJUVANT THERAPY TO CONTROL ADVANCED RETINOBLASTOMA

Q: How can I download an article?

To download an article from SID, first log in to the site, search for the article title, and click on the 'Download Article' option.

Q: How can I download an ISI article?

To download an ISI article on SID, enter the keyword or article title in the search bar, view the relevant results, click on the desired article, and select the 'Download Article' option.

Q: How can I access the SID database?

To access the SID database, visit SID.ir, create an account, and log in to access scientific resources.

Q: Is downloading articles from SID free?

Some articles on SID are available for free, while others require payment. Details are specified on the article's page.

NASERIPOOR M.; BAKHTIARI P.; ZARE MOGHDAM A.; VOSOUGH PARVANEH; SALAMI SH.; NASERIPOOR M.

مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Journal Paper

Paper Information

Journal: JOURNAL OF CURRENT OPHTHALMOLOGY Year:2005 | Volume:18 | Issue:4 Page(s): 91-98

Download Full-Text

Persian Verion

View:

968

Download:

Cites:

Information Journal Paper

Title

COMBINED CHEMOREDUCTION AND ADJUVANT THERAPY TO CONTROL ADVANCED RETINOBLASTOMA

Author(s)

Keywords

RETINOBLASTOMAQ4

CHEMOREDUCTIONQ4

ADJUVANT THERAPYQ4

Abstract

Objective: To evaluate the efficacy of CHEMOREDUCTION and adjuvant treatment for RETINOBLASTOMA (Rb) and its effects on complete retinal tumor control, ocular prognosis and metastasis.Design: Prospective, nonrandomized clinical trial.Participants: 30 eyes of 22 consecutive patients with 91 intraocular RETINOBLASTOMA tumors were enrolled and studied prospectively. Main Outcome Measures: The 3 main outcome measures included ocular prognosis, tumor prognosis and life prognosis. Mean follow-up was 14 months.Results: 30 eyes of 22 consecutive patients (10 males and 12 females) were treated. Mean patient age was 28.4 months. 16 eyes had Reese-Els worth (RE) group I-IV tumors, and 14 had RE group V tumors at diagnosis. 14 patients completed at least 6 cycles (range: 6-24 cycles) of chemotherapy with vincristin, etoposide and carboplatin.Of those eyes classified as RE group I-IV, external beam radiation therapy (EBRT) and enucleation were necessary in 3 (18.75%) and 1 eyes (6.25%) respectively; versus 4 (28.57%) and 7 eyes (50%) in those in group V. Kaplan-Meier analysis for globe survival showed 24 months survival of 55.0%. Subgroup comparison of globe survival demonstrated survival rate of 25.4% globes in eyes with RE stage V and 88.8% in eyes with stage IV b or less (Log Rank, P= 0.024). No patient developed RETINOBLASTOMA metastasis, pineoblastoma, or second malignant neoplasms during follow-up.Conclusion: CHEMOREDUCTION combined with focal treatment provides satisfactory RETINOBLASTOMA control for RE group I-IV. More effective modalities are required for advanced cases, particularly for RE group V tumors.

Cites

No record.

References

No record.

Cite

APA: Copy

NASERIPOOR, M., BAKHTIARI, P., ZARE MOGHDAM, A., VOSOUGH, PARVANEH, SALAMI, SH., & NASERIPOOR, M.. (2005). COMBINED CHEMOREDUCTION AND ADJUVANT THERAPY TO CONTROL ADVANCED RETINOBLASTOMA. JOURNAL OF CURRENT OPHTHALMOLOGY, 18(4), 91-98. SID. https://sid.ir/paper/53062/en

Vancouver: Copy

NASERIPOOR M., BAKHTIARI P., ZARE MOGHDAM A., VOSOUGH PARVANEH, SALAMI SH., NASERIPOOR M.. COMBINED CHEMOREDUCTION AND ADJUVANT THERAPY TO CONTROL ADVANCED RETINOBLASTOMA. JOURNAL OF CURRENT OPHTHALMOLOGY[Internet]. 2005;18(4):91-98. Available from: https://sid.ir/paper/53062/en

IEEE: Copy

M. NASERIPOOR, P. BAKHTIARI, A. ZARE MOGHDAM, PARVANEH VOSOUGH, SH. SALAMI, and M. NASERIPOOR, “COMBINED CHEMOREDUCTION AND ADJUVANT THERAPY TO CONTROL ADVANCED RETINOBLASTOMA,” JOURNAL OF CURRENT OPHTHALMOLOGY, vol. 18, no. 4, pp. 91–98, 2005, [Online]. Available: https://sid.ir/paper/53062/en

Related Journal Papers